Close

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program Feb 18, 2022 04:01PM
Orphazyme (ORPH) establishes $50M U.S. At-the-Market Offering Program with Cowen Nov 4, 2021 08:23AM
Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen Nov 4, 2021 08:22AM
Cowen Downgrades Orphazyme A/S (ORPHA:DC) (ORPH) to Market Perform, After Receiving FDA CRL Jun 18, 2021 03:54PM
Orphazyme announces participation in upcoming virtual investor conferences Feb 26, 2021 03:38PM


Dec 28, 2020 07:52AM Orphazyme (ORPH) Extension Should Not Raise Investor Concerns, Cowen Reiterates Outperform
Nov 3, 2020 04:44PM End of stabilization period
Oct 26, 2020 05:31AM Cowen Starts Orphazyme (ORPH) at Outperform
Oct 1, 2020 02:25AM Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Sep 30, 2020 08:21AM Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ord
Sep 30, 2020 06:10AM Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering
Sep 28, 2020 10:45PM Stabilization period begins
Sep 28, 2020 10:27PM Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe